嵌合抗原受体T细胞疗法作为二线对比三线对比四线及以上治疗侵袭性B细胞淋巴瘤的结局:来自ABC联盟的真实世界证据
该多中心回顾性分析纳入466例接受CD19靶向嵌合抗原受体T细胞疗法的LBCL患者,按治疗线数分为2L(21%)、3L(41%)和4L+(38%),中位随访35个月,2L与3L的PFS和OS相似,4L+则更短;在DHL/THL患者中2L较3L显著改善3年OS。
要点
- CART作为2L与3L的总缓解率和完全缓解率相似。
- CART作为4L+的中位PFS和中位OS均短于2L和3L。
- 在DHL/THL患者中,2L较3L的3年OS显著更优(63% vs 32%,P=.01)。
核心结论
- 在未经选择的患者中,CART作为2L与3L的生存结局相似,但DHL/THL患者应考虑在2L接受CART(排除原发性难治性疾病或早期复发情形)。
研究设计与样本
- 多中心回顾性分析,纳入466例接受CD19靶向CART治疗的原发弥漫性大B细胞淋巴瘤或转化性滤泡性淋巴瘤患者,按治疗线数分为2L(21%,n=98)、3L(41%,n=192)和4L+(38%,n=176),中位随访35个月。
主要发现
- 总缓解率和完全缓解率在2L、3L与4L+之间相似。
- 中位PFS在2L、3L与4L+分别为11.6、12.7与5.7个月(P<.001),中位OS分别为未达到、69.4与21.9个月(P<.001),2L与3L相似而4L+更短。
- 在DHL/THL患者中,2L较3L的3年OS显著改善(63% vs 32%,P=.01)。
- 需要桥接治疗的患者进展或死亡风险增加。
临床怎么用
- 作者认为,在未经选择的患者中CART作为2L与3L的生存结局相似。
- 作者认为,DHL/THL患者应考虑在2L接受CART(排除原发性难治性疾病或早期复发情形)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T-cell (CART) therapy has transformed the management of relapsed and refractory large B-cell lymphoma (LBCL), but real-world outcomes data is needed to confirm the benefits seen in clinical trial settings. We performed a multicenter retrospective analysis evaluating CART therapy outcomes according to line of therapy, specifically second line (2L) vs third line (3L) vs fourth line (4L) and beyond (4L+). We included patients who received CD19-directed CART therapy for de novo diffuse LBCL or transformed follicular lymphoma. Overall (N = 466), 21% (n = 98) of patients received CART as 2L, 41% (n = 192) as 3L, and 38% (n = 176) as 4L+. Median follow-up from CART infusion was 35 months. Overall response rate and complete response rate were similar for 2L vs 3L vs 4L+. From CART infusion, median progression-free survival (mPFS) and median overall survival (mOS) were similar for 2L vs 3L, but shorter in patients receiving CART as 4L+ (mPFS, 11.6 vs 12.7 vs 5.7 months, P< .001; mOS, not reached vs 69.4 vs 21.9 months, P< .001). In patients with double-hit or triple-hit lymphoma (DHL/THL), receiving CART in 2L vs 3L significantly improved 3-year OS (63% [2L] vs 32% [3L], P = .01). Patients with disease that required bridging therapy were also at increased risk of progression or death. Overall, our findings inform real-world practice wherein CART therapy as 2L vs 3L yields similar survival outcomes in unselected patients. However, patients specifically with DHL/THL should be considered for CART therapy in the 2L outside of the primary refractory disease (PRD) or early relapsed setting.
引用
- Wang JS, Ellsworth BL, Melody M, et al. Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium. Blood Adv. 2026. PMID: 41201962. doi:10.1182/bloodadvances.2025017120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。